UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 31, 2016

CEL-SCI CORPORATION
(Exact name of Registrant as specified in its charter)

      Colorado                        0-11503                  84-0916344
--------------------------      ------------------------  ---------------------
(State or other jurisdiction    (Commission File No.)         (IRS Employer
of incorporation)                                          Identification No.)

8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A
(Former name or former address if changed since last report)

Item 1.01. Entry into a Material Definitive Agreement.

See Item 5.02 of this report.

Item 3.02. Unregistered Sales of Equity Securities.

The shares of common stock described in Item 5.02 were not registered under the Securities Act of 1933 and are restricted securities. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with the issuance of these shares. The person who acquired these shares was a sophisticated investor and was provided full information regarding the Company's business and operations. There was no general solicitation in connection with the offer or sale of these securities. The person who acquired these shares acquired them for his own account. The certificates representing these shares will bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission was paid to any person in connection with the issuance of these shares.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Maximilian de Clara

Effective August 31, 2016 Maximilian de Clara resigned as an officer and director of the Company. Mr. de Clara's resignation was not due to any disagreements with the Company.

In consideration for Mr. de Clara's past services to the Company, the Company entered into a Termination Agreement with Mr. de Clara which provided for the following:

1. The Company agreed to issue 650,000 restricted shares of its common stock to Mr. de Clara. The first 325,000 shares will be issued promptly after August 31, 2016. Of the first 325,000 shares, none of the shares may be sold prior to February 28, 2017. Starting on February 28, 2017, each month the Company will remove the restrictive legend on 65,000 shares. The second 325,000 shares will be issued on August 31, 2017, but may not be sold prior to February 28, 2018. Starting on February 28, 2018, each month the Company will remove the restrictive legend on 65,000 shares. The foregoing procedure will continue until the restricted legend has been removed on all 650,000 shares.

2. All options held by Mr. de Clara will vest as of August 31, 2016.

3. Mr. de Clara's existing coverage under the Company's group health plan will end on August 31, 2016. However, Mr. de Clara may be eligible to elect temporary continuation coverage under the Company's group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). If Mr. de Clara elects COBRA continuation coverage, the Company will pay for COBRA coverage (such payments will not include COBRA coverage with respect to the Company's

2

Section 125 health care reimbursement plan) until February 28, 2018, or the maximum period permitted under COBRA if such period is less than eighteen months. If Mr. de Clara exhausts the applicable COBRA period prior to February 28, 2018, the Company will reimburse Mr. de Clara for the cost of an individual health insurance policy in an amount not to exceed the amount of the monthly COBRA premium previously paid by the Company.

The Termination Agreement was approved by the Company's Compensation Commmittee.

The foregoing description of the Termination Agreement is qualified in its entirety by reference to the full text of the Termination Agreement attached as an exhibit to this report.

Employment Agreements

On August 31, 2016, CEL-SCI entered into a three-year employment agreement with Geert Kersten, CEL-SCI's Chief Executive Officer. The employment agreement with Mr. Kersten, which is essentially the same as Mr. Kersten's prior employment agreement, as amended on August 30, 2013, provided that, during the term of the agreement, CEL-SCI would pay Mr. Kersten an annual salary of $559,052, plus any increases in proportion to salary increases granted to other senior executive officers of CEL-SCI, as well any increases approved by the Board of Directors during the period of the employment agreement.

On August 31, 2016, CEL-SCI entered into a three-year employment agreement with Patricia B. Prichep, CEL-SCI's Senior Vice President of Operations. The employment agreement with Ms. Prichep, which is essentially the same as Ms. Prichep's prior employment agreement entered into on August 30, 2013 provided that, during the term of the agreement, CEL-SCI would pay Ms. Prichep an annual salary of $245,804 plus any increases approved by the Board of Directors during the period of the employment agreement.

On August 31, 2016, CEL-SCI entered into a three-year employment agreement with Eyal Talor, Ph.D., CEL-SCI's Chief Scientific Officer. The employment agreement with Dr. Talor, which is essentially the same as Dr. Talor's prior employment agreement entered into on August 30, 2013, provided that, during the term of the agreement, CEL-SCI would pay Dr. Talor an annual salary of $303,453 plus any increases approved by the Board of Directors during the period of the employment agreement.

The employment agreements were approved by CEL-SCI's Compensation Committee. In renewing the employment agreements with the persons mentioned above, CEL-SCI's Compensation Committee considered various factors, including each employee's performance in their area of responsibility, each employee's experience in his or her position, and each employee's length of service with CEL-SCI.

The foregoing description of the Employment Agreements are qualified in their entirety by reference to the full text of the Employment Agreements attached as exhibits to this report.

3

Item 8.01 Other Events.

Update on Phase 3 clinical trial

CEL-SCI's Phase 3 head and neck cancer study objective is to measure whether an improvement in overall survival can be achieved in the patient group that receives CEL-SCI's investigational drug Multikine treatment regimen plus the Standard of Care treatment (SOC) vs. the group that receives the SOC alone. This assessment can only be made when a certain number of deaths have occurred in these two main comparator groups of the study. The currently available data from the Clinical Study reflect that the accumulation of deaths is lower than that which was anticipated based on reported literature at the Phase 3 Study's inception. If the number of deaths continue to be accumulated at the current rate, it has been determined that it will take longer than originally planned to complete the study. To minimize this eventuality, CEL-SCI has decided to enroll up to 1,273 patients to have 1,146 evaluable patients. With this increased patient enrollment the Company expects a corresponding increase in the number of deaths, and the study could be completed more timely.

Under the expanded Phase 3 protocol, the duration of the follow-up period, and therefore the length of the study, will depend on how soon 392 deaths have occurred in the two main comparator groups of the study. A difference of 6.5% in overall survival in favor of the Multikine treated group will signify superiority over treatment with SOC alone.

Current enrollment in the Phase 3 study as of September 1, 2016 is 905 patients. Since the data generated under the former Clinical Research Organization (CRO) cannot be pooled with the subsequent data, the Phase 3 study will be considered to have "restarted" in October 2013, the date the new CROs assumed complete responsibility for the management of the study. The 125 patients who had been enrolled in the study before October 2013 will be evaluable in the Phase 3 study for safety only. To reach full enrollment the Company will therefore enroll a further 125 patients in addition to the increase in planned enrollment outlined above.

The regulatory bodies of several countries have already cleared the changes for the study. The review process in other countries remains ongoing. The full implementation of these changes will not be possible unless the regulators in the countries with the top patient enrollment agree to the changes.

Arbitration Hearing

The Company's arbitration hearing, brought by the Company against its former Clinical Research Organization which previously ran the Company's Phase 3 clinical trial, has been scheduled to begin on September 26, 2016.

4

Item 9.01   Financial Statements and Exhibits.

Exhibit    Description
-------    -----------

10(lll)    Termination Agreement with Maximilian de Clara.

10(mmm)    Employment Agreement with Geert Kersten (2016).

10(nnn)    Employment Agreement with Patricia Prichep (2016).

10(ooo)    Employment Agreement with Eyal Talor (2016).

5

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  September 1, 2016              CEL-SCI CORPORATION



                                    By: /s/ Patricia B. Prichep
                                        -------------------------------------
                                        Patricia B. Prichep
                                        Senior Vice President of Operations


EXHIBIT 10(lll)


TERMINATION AGREEMENT

THIS AGREEMENT, made and entered into as of August 25, 2016, by and between CEL-SCI CORPORATION ("the Company") and Maximilian de Clara ("de Clara").

In consideration of the mutual agreements, terms, and conditions herein contained, the Company and de Clara agree as follows:

1. Resignation. de Clara has tendered his resignation as an employee, executive officer and director of the Company, and the Company has accepted such resignation, to be effective as of August 31, 2016. The parties hereby expressly agree that (i) de Clara shall cease to be an employee, officer and director of the Company as of August 31, 2016, and (ii) the Employment Agreement between the Company and de Clara will not be renewed.

2. Issuance/Sale of Shares. In consideration for de Clara's past services to the Company, the Company will issue 650,000 shares of its common stock to de Clara with a restrictive legend. Half of these shares will be given upon signing this agreement. The other half will be given on August 31, 2017. Of the first 325,000 shares none of the shares may be sold prior to February 28, 2017. Starting on February 28, 2017, each month the Company will remove the restrictive legend on 65,000 shares. On the second 325,000 shares due on August 31, 2017, none of the shares may be sold prior to February 28, 2018. Starting on February 28, 2018, each month the Company will remove the restrictive legend on 65,000 shares. The foregoing procedure will continue until the restricted legend has been removed on all 650,000 shares.

3. Options. All options held by de Clara will vest as of August 31, 2016.

4. Health Insurance. de Clara's existing coverage under the Company's group health plan will end on August 31, 2016. de Clara may then be eligible to elect temporary continuation coverage under the Company's group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). de Clara will be provided with a COBRA election form and notice which will describe his rights to continuation coverage under COBRA. If de Clara elects COBRA continuation coverage, then the Company will pay for COBRA coverage (such payments shall not include COBRA coverage with respect to the Company's Section 125 health care reimbursement plan) until February 28, 2018, or (ii) the maximum period permitted under COBRA if such period is less than eighteen months. If de Clara exhausts the applicable COBRA period, the Company will reimburse de Clara for the cost of an individual health insurance policy in an amount not to exceed the amount of the monthly COBRA premium previously paid by the Company pursuant to this paragraph. After such period of Company-paid coverage, de Clara may continue coverage at his own expense in accordance with COBRA or other applicable laws. No provision of this agreement will affect the continuation coverage rules under COBRA. In the event, however, de Clara becomes eligible for benefits under another plan prior to February 28, 2018, the Company shall no longer be obligated to pay such benefit premiums. de Clara is required to notify the Company of his eligibility for benefits under another plan and is expected to enroll in the new plan at the first eligible opportunity unless de Clara chooses, at de Clara's sole expense, to continue COBRA benefits through the Company. If de Clara fails to notify the Company of de Clara's eligibility

1

for alternative benefits, the Company shall have the right to discontinue payment of COBRA premiums upon thirty (30) days' notice to de Clara. In no event shall a cash payment be made to de Clara in lieu of the payment of COBRA premiums.

5. Taxes. de Clara shall be responsible for the payment of all tax or other liabilities which de Clara incurs due to the receipt of the shares, and de Clara expressly agrees to indemnify and hold the Company harmless from any and all tax liabilities which may be imposed upon the Company at any time by any governmental agency, whether federal, state, or provincial, as a result of this Agreement.

6. Release. In consideration for the issuance of the shares, de Clara does hereby release and forever discharge the Company, including its officers, directors, employees, attorneys and agents, of and from any and all claims, demands, losses, obligations, liabilities, compensatory damages, punitive damages, statutory damages, attorneys' fees, costs, expenses, rights of action and causes of action of any kind or character whatsoever, whether known or unknown, arising prior to the execution of this Agreement. de Clara understands and hereby acknowledges that he may hereafter discover facts and legal theories in addition to or different from those of which he now believes to be true. However, de Clara understands and hereby agrees that his release shall remain effective in all respects notwithstanding those additional or different facts and legal theories or the discovery of those additional or different facts or legal theories.

7. Notices. All notices required or permitted to be given under this Agreement shall be in writing and shall be delivered by courier, mailed (postage prepaid) addressed as follows, or sent via email to the email address shown below:

In case of notice to the Company:

Patricia Prichep
CEL-SCI Corporation
8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 Email address: pprichep@cel-sci.com

In case of notice to de Clara:

Maximilian de Clara
Bergstrasse 79
6078 Lungern,
Obwalden, Switzerland

The address of either party hereto may be changed by written notice to the other party hereto given in the manner hereinabove described. All such notices shall be deemed to have been given when delivered, mailed or sent as aforesaid.

2

8. Governing Law/Arbitration. This Agreement will construed in accordance with the laws of Colorado, without giving effect to conflict of law principles. Any dispute or claim in any way involving this Agreement will be settled through binding arbitration pursuant to the Commercial Rules of the American Arbitration Association in Washington, D.C.

9. Miscellaneous Provisions. This Agreement contains the entire Agreement and understanding between the parties hereto, and supersedes all prior agreements or understandings between the parties. No representations were made or relied upon by either party, other than those that are expressly set forth. The section headings throughout this Agreement are for convenience and reference only, and shall in no way be deemed to define, limit, or add to the meaning of any provision of this Agreement. This Agreement and any provision hereof, may not be waived, changed, modified, or discharged orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, or discharge is sought. Except as otherwise expressly provided herein, no waiver of any covenant, condition, or provision of this Agreement shall be deemed to have been made unless expressly in writing and signed by the party against whom such waiver is charged; and (i) the failure of any party to insist in any one or more cases upon the performance of any of the provisions, covenants, or conditions of this Agreement or to exercise any option herein contained shall not be construed as a waiver or relinquishment for the future of any such provisions, covenants, or conditions, (ii) the acceptance of performance of anything required by this Agreement to be performed with knowledge of the breach or failure of a covenant, condition, or provision hereof shall not be deemed a waiver of such breach or failure, and (iii) no waiver by any party of one breach by another party shall be construed as a waiver with respect to any other or subsequent breach. This Agreement shall inure to and be binding upon the heirs, executors, personal representatives, successors and assigns of each of the parties to this Agreement. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement which shall continue in full force and effect except for any such invalid or unenforceable provision. Neither party shall assign this Agreement without the prior express written consent of the other party.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective the day and year first above written.

CEL-SCI CORPORATION

By: /s/ Peter Young, MD.
    ---------------------------------------
    Dr.   Peter   Young,   Chairman  of  the
    Compensation Committee


    /s/ Maximilian de Clara
    ---------------------------------------
    Maximilian de Clara

3

EXHIBIT 10(mmm)


EMPLOYMENT AGREEMENT

This Employment Agreement ("AGREEMENT") is made by and between Geert R. Kersten ("EMPLOYEE") and CEL-SCI Corporation ("CEL-SCI" or "the Company") as of August 31, 2016 (the "Effective Date").

RECITALS

EMPLOYEE has been an EMPLOYEE of CEL-SCI since February 1987. CEL-SCI and EMPLOYEE wish to set forth in this AGREEMENT the terms and conditions under which EMPLOYEE is to be employed by CEL-SCI from the date of execution forward.

In consideration of EMPLOYEE's agreement to continue providing services to CEL-SCI, CEL-SCI's agreement to employ EMPLOYEE on the terms and conditions set forth herein and the mutual agreements set forth herein, the parties hereto agree as follows:

1. Term And Nature Of Employment

CEL-SCI hereby employs EMPLOYEE as Chief Executive Officer of CEL-SCI commencing on the Effective Date of this AGREEMENT and ending on August 31, 2019, unless said period of employment (the "Employment Period") is terminated earlier in accordance with the terms of this AGREEMENT. Thereafter, EMPLOYEE shall be employed on an at-will basis and may terminate and may be terminated from his employment with or without cause. EMPLOYEE hereby accepts such employment and agrees to devote his full business time and attention, best efforts, energy and skills to the business and affairs of CEL-SCI. EMPLOYEE agrees to perform such other duties as may from time to time be assigned to him by the Board of Directors of CEL-SCI and shall act at all times in accordance with the best interests of CEL-SCI. EMPLOYEE agrees that he shall comply with all applicable governmental laws, rules and regulations and with all of CEL-SCI's policies, rules and/or regulations applicable to the employees of CEL-SCI.

2. Wage Compensation

2.1 EMPLOYEE shall be compensated on the basis of an annual salary of $559,052, less applicable withholding taxes. Employee will receive at least the same salary increases per year as do other senior executives of CEL-SCI. Increases beyond those, if any, shall be made at the sole discretion of the Board of Directors of CEL-SCI. Nothing in this paragraph 2.1 shall be construed to limit CEL-SCI's right to terminate this AGREEMENT in accordance with the terms hereof.

2.2 Payment.

Salary payments will normally be made to EMPLOYEE semi-monthly or otherwise in accordance with CEL-SCI's pay period practices applicable to executive officers.

1

3. Other Benefits.

3.1 During the Employment Period, EMPLOYEE shall be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time Employees, in accordance with CEL-SCI's policies and practices and subject to EMPLOYEE's satisfaction of any applicable condition of eligibility.

3.2 Reimbursement of Expenses. CEL-SCI shall reimburse EMPLOYEE for all reasonable business expenses incurred by EMPLOYEE on behalf of CEL-SCI provided that: (i) such reasonable expenses are ordinary and necessary business expenses incurred on behalf of CEL-SCI, and (ii) EMPLOYEE provides CEL-SCI with itemized accounts, receipts and other documentation for such reasonable expenses as are reasonably required by CEL-SCI. Any expenses found not to be reasonable business expenses by the auditors or the IRS will be reimbursed to the Company by the EMPLOYEE.

4. Former Employment

No Conflict. EMPLOYEE represents and warrants that the execution and delivery by him of this AGREEMENT, his employment by CEL-SCI and his performance of duties under this AGREEMENT will not conflict with and will not be constrained by any prior employment or consulting agreement or relationship, or any other contractual obligations.

5. Termination

5.1.a Termination of AGREEMENT Due to Death or Disability. EMPLOYEE's employment and this AGREEMENT shall terminate upon EMPLOYEE's death. In the event that EMPLOYEE's employment ends due to his death, CEL-SCI's obligations under this AGREEMENT shall immediately cease, except that the EMPLOYEE's legal representatives shall be entitled to receive all compensation otherwise payable to EMPLOYEE through the last day of the month in which the EMPLOYEE's death occurred. If EMPLOYEE dies while employed by CEL-SCI, any options or stock of the Company then owned by EMPLOYEE shall automatically accelerate and become fully vested. This provision shall not otherwise limit any benefits available under CEL-SCI's benefit plans. The exercise period of any stock options held by EMPLOYEE at his death will be extended pursuant to the provisions of any stock option plan or agreement pursuant to which the options were granted.

5.1.b. If EMPLOYEE becomes mentally or physically incapacitated or disabled so as to be unable to perform EMPLOYEE's duties under this agreement, the AGREEMENT shall terminate as well. Employee's inability to adequately perform services under this AGREEMENT for a period of ninety (90) consecutive days will be conclusive evidence of such mental or physical incapacity or disability, unless such inability to adequately perform such services under this AGREEMENT is pursuant to a mental or physical incapacity or disability covered by the Family Medical Leave Act ("FMLA"). If EMPLOYEE becomes disabled while employed by CEL-SCI, any options or stock of the Company then owned by EMPLOYEE shall automatically accelerate and become fully vested. This provision shall not otherwise limit any benefits available under CEL-SCI's benefit plans. CEL-SCI

2

shall also extend the period of exercisability of those stock options to four years, or the natural expiration of the stock options, whichever is later.

5.2 "Termination for Cause". Notwithstanding anything to the contrary herein, EMPLOYEE's employment and this AGREEMENT may be terminated by CEL-SCI upon written notification upon the occurrence of any of the following:

a. Willful misconduct that has a material adverse effect on CEL-SCI's operations, prospects, and business.

b. Acts of fraud against CEL-SCI.

c. EMPLOYEE breaches any of the terms or conditions set forth in this AGREEMENT and EMPLOYEE fails to cure such breach within 30 days after EMPLOYEE's receipt from CEL-SCI of written notice of such breach, which notice shall describe in reasonable detail CEL-SCI's belief that EMPLOYEE is in breach hereof (notwithstanding the following, no cure period shall be applicable to breaches by EMPLOYEE of paragraphs 6 and 7 or to the extent CEL-SCI has provided EMPLOYEE more than 2 notices of substantially the same breach within any 12 month period).

In the event that EMPLOYEE's employment is terminated with cause by CEL-SCI pursuant to this paragraph 5.2 of this AGREEMENT, CEL-SCI obligations under this AGREEMENT shall immediately cease.

Termination of EMPLOYEE pursuant to this section 5.2 shall be in addition to and without prejudice to any other right or remedy to which CEL-SCI may be entitled at law, in equity, or under this AGREEMENT.

5.3 Constructive Termination.

If during the period commencing on the date that is 12 months prior to the occurrence of a Change in Control and ending on the date that is 48 months following a Change in Control, (i) the Company terminates Employee's employment, or other than for cause, the Employee terminates his employment with the Company, or (ii) the Employee terminates his employment for Good Reason (both a "Constructive Termination"), then;

o all stock options under any Company Stock Option Plan which Employee holds at the time of such Constructive Termination shall become fully vested;

o the Company will extend the expiration date of the stock options referred to above to a date which is four years after the effective date of the Employee's resignation, unless the expiration date is after such four-year period, in which case the original expiration date will control;

o all outstanding restricted stock, which is the subject of an Award Agreement pursuant to the Company's 2014 Incentive Stock Bonus Plan; shall vest; and

3

o all restrictions pertaining to any award made pursuant to the Company's 2014 Incentive Stock Bonus Plan shall lapse and have no further force and effect, including the failure to meet the Performance Criteria set forth in the Award Agreement pursuant to the Company's 2014 Incentive Stock Bonus Plan.

For purposes of the above:

"Change of Control" shall mean a change in ownership or control of the Company affected through any of the following transactions:

a. a merger, consolidation or reorganization approved by the Company's stockholders, unless securities representing more than 50% of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly, and in substantially the same proportion, by the persons who beneficially owned the company's outstanding voting securities immediately prior to such transaction, or

b. any stockholder-approved transfer or other disposition of all or substantially all of the Company's assets, or

c. The acquisition by any individual, entity or group of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) of 20% or more of the Company's either (1) the then outstanding shares of common stock of the Company or (2) the combined voting power of the then outstanding voting securities of the Company entitled to vote in the election of directors, or

d. a change in the composition of the Board over a period of thirty-six
(36) months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.

Good Reason means: (a) a reduction in the Employee's compensation (including benefits); or (b) the Employee being assigned any duties which are materially inconsistent with the duties of the Employee immediately prior to the occurrence of the Constructive Termination; or (c) the office at which the Employee performs his duties is more than 10 miles from the office at which the Employee performed his duties immediately prior to the occurrence of the Constructive Termination.

In the event a Constructive Termination has occurred EMPLOYEE shall, in his sole discretion, provide Company with his written notice of resignation to be effective not less than 30 days after receipt by Company, whereupon EMPLOYEE shall cease to be employed by the Company and both parties shall be

4

relieved of further responsibility or liability to the other under this Agreement, other than as provided in this AGREEMENT. Upon receipt of such notice of resignation, Company shall promptly pay to EMPLOYEE by certified check, wire transfer funds, or other form of payment reasonably acceptable to EMPLOYEE, a lump sum amount equal to 24 months salary of the EMPLOYEE at such compensation rate as is then in effect under the terms of this Agreement and any extension or renewal thereof (the "Payment"), or the value of the remaining employment contract, whichever is greater. The Payment shall not have deducted from it any charges, expenses, debts, set-offs or other deductions of any kind whatsoever except for required taxes.

5.4 In the event of a Constructive Termination, the Company shall also provide the following benefits to EMPLOYEE:

a. The EMPLOYEE's existing coverage under the Company's group health plan (and, if applicable, the existing group health coverage for eligible dependents) will end on the last day of the month in which the eligible EMPLOYEE's employment terminates. The eligible EMPLOYEE and his eligible dependents may then be eligible to elect temporary continuation coverage under the Company's group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). The eligible EMPLOYEE (and, if applicable, his eligible dependents) will be provided with a COBRA election form and notice which describe his rights to continuation coverage under COBRA. If an eligible EMPLOYEE elects COBRA continuation coverage, then the Company will pay for COBRA coverage (such payments shall not include COBRA coverage with respect to the Company's Section 125 health care reimbursement plan) for (i) eighteen (18) months, or (ii) the maximum period permitted under COBRA. If EMPLOYEE does exhaust the applicable COBRA period, the Company will reimburse EMPLOYEE for the cost of an individual health insurance policy in an amount not to exceed the amount of the monthly COBRA premium previously paid by the Company pursuant to this paragraph for the remainder of the two year period following EMPLOYEE's termination of employment. After such period of Company-paid coverage, the eligible EMPLOYEE (and, if applicable, his eligible dependents) may continue coverage at his own expense in accordance with COBRA or other applicable laws. No provision of this agreement will affect the continuation coverage rules under COBRA. Therefore, the period during which the eligible EMPLOYEE must elect to continue the Company's health plan coverage under COBRA, the length of time during which COBRA coverage will be made available to the eligible EMPLOYEE, and all the eligible EMPLOYEE's other rights and obligation under COBRA will be applied in the same manner that such rules would apply in the absence of the Plan. In the event, however, an EMPLOYEE becomes eligible for benefits under another plan prior to the expiration of the period in which the Company is paying benefit premiums, the Company shall no longer be obligated to pay such benefit premiums. The EMPLOYEE is required to notify the Company of eligibility for benefits under another plan and is expected to enroll in the new group plan at the first eligible opportunity unless EMPLOYEE chooses, at EMPLOYEE's sole expense, to continue COBRA benefits through the Company. If EMPLOYEE fails to notify the Company of EMPLOYEE's eligibility for alterative benefits, the Company shall have the right to discontinue payment of COBRA premiums upon thirty (30) days' notice to EMPLOYEE. In no event shall a cash payment be made to EMPLOYEE in lieu of the payment of COBRA premiums. The payment of COBRA premiums by the Company shall not extend the maximum eligible COBRA coverage period.

5

b. Outplacement Services. The Company will make available to EMPLOYEE, upon his request, outplacement services provided by a reputable outplacement counselor selected by the Company for a period of nine months following termination. The Company will assume the cost of all such outplacement services. In no event will a cash payment be made in lieu of outplacement benefits.

6. Confidentiality

6.1 In view of the fact that the EMPLOYEE's work for the Company will bring his into close contact with many confidential affairs of the Company not readily available to the public, the EMPLOYEE agrees:

6.1.1 To keep secret and retain in the strictest confidence, all confidential matters of the Company, including, without limitation, inventions and related proprietary information, trade secrets, patents, customer lists, methods, scientific results and related documentation in connection with any research and development undertaken by, or at the direction of, the Company, confidential pricing policies, confidential utilization review protocols and screens, confidential and proprietary operational methods and other confidential and proprietary business affairs and plans of the Company and its affiliates, learned by his heretofore or hereafter; and not to disclose them to anyone outside the Company, except in the course of performing his duties hereunder or with the Company's express written consent; and

6.1.2 To promptly deliver to the Company upon the termination of his employment with the Company, or at any time the Company may so request, all memoranda, notes, records, reports, manuals, and other documents (and all copies thereof) relating to the Company's business and all property associated therewith, which he may then possess or have under his control.

6.2 If the EMPLOYEE commits a breach, or threatens to commit a breach, of any of the provisions of Section 6.1 hereof, the Company shall have the following rights and remedies:

6.2.1 The rights and remedy to have the provisions of this Agreement specifically enforced by any court of competent jurisdiction, it being acknowledged that any such breach or threatened breach shall cause irreparable injury to the Company, and that money damages shall not provide a complete and adequate remedy to the Company;

Each of the rights and remedies enumerated above shall be independent of the other and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity.

7. Non-Competition and Non-Solicitation of Employees/Inventions, Patents and Copyrights

7.1 EMPLOYEE agrees and promises that if his employment is terminated, then, for the period of time described below, he will not be engaged in any other business or as a consultant to or general partner, employee, officer or director of any partnership, firm, corporation, or other entity, or as an agent for any person, or otherwise, if: (1) such other business, partnership, firm,

6

corporation, entity or person is engaged in for-profit activity in the pharmaceutical industry within the United States and competes with the Company in the field of natural cytokine mixtures for the treatment of any cancer indication the Company is pursuing in clinical trials; and (2) EMPLOYEE either
(a) is a senior officer of such other business, partnership, firm, corporation, entity or person; or (b) participates in or directs the development of drugs for the treatment of cancer for such other business, partnership, firm, corporation, entity or person. This agreement to refrain from engaging in competitive activities shall continue for the period during which the Company is required by the terms of paragraphs 5.2 or 5.3 of this Agreement to make salary payments to EMPLOYEE following his termination (i.e., twenty four (24) months in the case of Constructive Termination under paragraph 5.3), or for 2 years in the case of the EMPLOYEE's resignation or termination pursuant to Section 5.2.

7.2 The EMPLOYEE further agrees and represents that during the EMPLOYEE's employment by the Company and during the period in which EMPLOYEE is subject to the Non-Competition provisions of this AGREEMENT, the EMPLOYEE will not, directly or indirectly, on the EMPLOYEE's own behalf or in the service of, or on behalf of any other individual or entity, divert, or attempt to divert, solicit or hire away, to or for any individual or entity which is engaged in providing business services, any person employed by the Company, whether or not such EMPLOYEE is employed pursuant to a written agreement and whether or not such EMPLOYEE is employed for a determined period or at-will.

7.3 All inventions made by the EMPLOYEE during the employment term, which inventions apply to the Company's business, including any improvements to any invention in existence as of the date of this Agreement, will be assigned to the Company. In the event any of such inventions are of a patentable nature, EMPLOYEE agrees to apply for a patent on the invention and assign any patent rights relating to the invention to the Company. The Company will bear the costs of any such patent applications.

7.4 EMPLOYEE understands that the Company's duties may involve writing or drafting various documents, for the Company. EMPLOYEE hereby assigns any and all rights to such documents to the Company, together with the right to secure copyright therefor and all extensions and renewals of copyright throughout the entire world. The Company shall have the right to make any and all versions, omissions, additions, changes, specifications and adaptions, in whole or in part, with respect to such documents, brochures or publications.

8. Notices.

All notices, requests, consents and other communications, required or permitted to be given hereunder, shall be in writing and shall be deemed to have been duly given if delivered personally or sent by prepaid electronic transmission or mailed first-class, postage prepaid, by registered or certified mail or delivered by an overnight courier service (notices sent by electronic transmission, mail or courier service shall be deemed to have been given on the date sent, or to such other address as either party shall designate by notice in writing to the other in accordance herewith).

7

9. Arbitration

The parties agree that any and all disputes that they have with one another which arise out of EMPLOYEE's employment or under the terms of this AGREEMENT shall be resolved through final and binding arbitration, as specified herein. This shall include, without limitation, disputes relating to this AGREEMENT, EMPLOYEE's employment by the Company or the termination thereof, claims for breach of contract or breach of the covenant of good faith and fair dealing, and any claims of discrimination or other claims under any federal, state or local law or regulation now in existence or hereinafter enacted and as amended from time to time concerning in any way the subject of EMPLOYEE's employment with the Company or its termination. The only claims not covered by this paragraph 9 are claims for benefits under the workers' compensation laws or claims for unemployment insurance benefits, which will be resolved pursuant to those laws, or the Company's rights pursuant to Section 6.2.1, which may be enforced by any court of competent jurisdiction. Binding arbitration will be conducted in the Washington, D.C. metropolitan area, in accordance with the rules and regulations of the American Arbitration Association. Each party will bear one half of the cost of the arbitration filing and hearing fees, and the cost of the arbitrator. Each party will bear its own attorneys' fees, unless otherwise decided by the arbitrator. EMPLOYEE understands and agrees that the arbitration shall be instead of any civil litigation and that the arbitrator's decision shall be final and binding to the fullest extent permitted by law and enforceable by any court having jurisdiction thereof.

10. General.

10.1 This Agreement shall be governed by, and enforced in accordance with, the laws of the Commonwealth of Virginia.

10.2 The article and section headings in this Agreement are for reference only and shall not in any way affect the interpretation of this Employment Agreement.

10.3 This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof.

10.4 This Agreement, and the EMPLOYEE'S rights and obligations hereunder, may not be assigned by the EMPLOYEE. The Company may assign this Agreement and its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets subject to Section 5.3 hereof; in any event, the obligations of the Company hereunder shall be binding on its successors or assigns, whether by merger, consolidation of acquisition of all or substantially all of its business or assets.

10.5 This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms hereof may be waived, only by a written instrument executed by both of the parties hereto or, in the case of a waiver, by the party waiving compliance. The failure of either party at any time or

8

times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. No waiver by either party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant in this Agreement.

11. Subsidiaries and Affiliates.

As used herein, the term "subsidiary" shall mean any corporation or other business entity controlled by the corporation in question; and the term "affiliate" shall mean and include any corporation or other business entity controlling, controlled by, or under common control with the corporation in question.

12. Survival.

Sections 6 and 7 of this Agreement shall survive termination of this Agreement for any reason.

IN WITNESS WHEREOF, the parties have executed this Agreement as of August 31, 2016.

CEL-SCI CORPORATION

/s/ Patricia B. Prichep
-----------------------------------------
By: Patricia B. Prichep
    Senior Vice President of Operations

EMPLOYEE

/s/ Geert R. Kersten
------------------------------------
Geert R. Kersten

9

EXHIBIT 10(nnn)


EMPLOYMENT AGREEMENT

This Employment Agreement ("AGREEMENT") is made by and between Patricia B. Prichep ("EMPLOYEE") and CEL-SCI Corporation ("CEL-SCI" or "the Company") as of August 31, 2016 (the "Effective Date").

RECITALS

EMPLOYEE has been an EMPLOYEE of CEL-SCI since December 1, 1992. CEL-SCI and EMPLOYEE wish to set forth in this AGREEMENT the terms and conditions under which EMPLOYEE is to be employed by CEL-SCI from the date of execution forward.

In consideration of EMPLOYEE's agreement to continue providing services to CEL-SCI, CEL-SCI's agreement to employ EMPLOYEE on the terms and conditions set forth herein and the mutual agreements set forth herein, the parties hereto agree as follows:

1. Term And Nature Of Employment

CEL-SCI hereby employs EMPLOYEE as Senior Vice President of Operations of CEL-SCI commencing on the Effective Date of this AGREEMENT and ending on August 31, 2019, unless said period of employment (the "Employment Period") is terminated earlier in accordance with the terms of this AGREEMENT. Thereafter, EMPLOYEE shall be employed on an at-will basis and may terminate and may be terminated from her employment with or without cause. EMPLOYEE hereby accepts such employment and agrees to devote her full business time and attention, best efforts, energy and skills to the business and affairs of CEL-SCI. EMPLOYEE agrees to perform such other duties as may from time to time be assigned to her by the Chief Executive Officer or the Board of Directors of CEL-SCI and shall act at all times in accordance with the best interests of CEL-SCI. EMPLOYEE agrees that she shall comply with all applicable governmental laws, rules and regulations and with all of CEL-SCI's policies, rules and/or regulations applicable to the employees of CEL-SCI.

2. Wage Compensation

2.1 EMPLOYEE shall be compensated on the basis of an annual salary of $245,804, less applicable withholding taxes. Increases in salary, if any, shall be made at the sole discretion of the Board of Directors of CEL-SCI. Nothing in this paragraph 2.1 shall be construed to limit CEL-SCI's right to terminate this AGREEMENT in accordance with the terms hereof.

2.2 Payment.

Salary payments will normally be made to EMPLOYEE semi-monthly or otherwise in accordance with CEL-SCI's pay period practices applicable to executive officers.

1

3. Other Benefits.

3.1 During the Employment Period, EMPLOYEE shall be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time Employees, in accordance with CEL-SCI's policies and practices and subject to EMPLOYEE's satisfaction of any applicable condition of eligibility.

3.2 Reimbursement of Expenses. CEL-SCI shall reimburse EMPLOYEE for all reasonable business expenses incurred by EMPLOYEE on behalf of CEL-SCI provided that: (i) such reasonable expenses are ordinary and necessary business expenses incurred on behalf of CEL-SCI, and (ii) EMPLOYEE provides CEL-SCI with itemized accounts, receipts and other documentation for such reasonable expenses as are reasonably required by CEL-SCI. Any expenses found not to be reasonable business expenses by the auditors or the IRS will be reimbursed to the Company by the EMPLOYEE.

4. Former Employment

No Conflict. EMPLOYEE represents and warrants that the execution and delivery by her of this AGREEMENT, her employment by CEL-SCI and her performance of duties under this AGREEMENT will not conflict with and will not be constrained by any prior employment or consulting agreement or relationship, or any other contractual obligations.

5. Termination

5.1.a Termination of AGREEMENT Due to Death or Disability. EMPLOYEE's employment and this AGREEMENT shall terminate upon EMPLOYEE's death. In the event that EMPLOYEE's employment ends due to her death, CEL-SCI's obligations under this AGREEMENT shall immediately cease, except that the EMPLOYEE's legal representatives shall be entitled to receive all compensation otherwise payable to EMPLOYEE through the last day of the month in which the EMPLOYEE's death occurred. If EMPLOYEE dies while employed by CEL-SCI, any options or stock of the Company then owned by EMPLOYEE shall automatically accelerate and become fully vested. This provision shall not otherwise limit any benefits available under CEL-SCI's benefit plans. The exercise period of any stock options held by EMPLOYEE at her death will be extended pursuant to the provisions of any stock option plan or agreement pursuant to which the options were granted.

5.1.b. If EMPLOYEE becomes mentally or physically incapacitated or disabled so as to be unable to perform EMPLOYEE's duties under this agreement, the AGREEMENT shall terminate as well. Employee's inability to adequately perform services under this AGREEMENT for a period of ninety (90) consecutive days will be conclusive evidence of such mental or physical incapacity or disability, unless such inability to adequately perform such services under this AGREEMENT is pursuant to a mental or physical incapacity or disability covered by the Family Medical Leave Act ("FMLA"). If EMPLOYEE becomes disabled while employed by CEL-SCI, any options or stock of the Company then owned by EMPLOYEE shall automatically accelerate and become fully vested. This provision shall not

2

otherwise limit any benefits available under CEL-SCI's benefit plans. CEL-SCI shall also extend the period of exercisability of those stock options to four years, or the natural expiration of the stock options, whichever is later.

5.2 "Termination for Cause". Notwithstanding anything to the contrary herein, EMPLOYEE's employment and this AGREEMENT may be terminated by CEL-SCI upon written notification upon the occurrence of any of the following:

a. Willful misconduct that has a material adverse effect on CEL-SCI's operations, prospects, and business.

b. Acts of fraud against CEL-SCI.

c. EMPLOYEE breaches any of the terms or conditions set forth in this AGREEMENT and EMPLOYEE fails to cure such breach within 30 days after EMPLOYEE's receipt from CEL-SCI of written notice of such breach, which notice shall describe in reasonable detail CEL-SCI's belief that EMPLOYEE is in breach hereof (notwithstanding the following, no cure period shall be applicable to breaches by EMPLOYEE of paragraphs 6 and 7 or to the extent CEL-SCI has provided EMPLOYEE more than 2 notices of substantially the same breach within any 12 month period).

In the event that EMPLOYEE's employment is terminated with cause by CEL-SCI pursuant to this paragraph 5.2 of this AGREEMENT, CEL-SCI obligations under this AGREEMENT shall immediately cease.

Termination of EMPLOYEE pursuant to this section 5.2 shall be in addition to and without prejudice to any other right or remedy to which CEL-SCI may be entitled at law, in equity, or under this AGREEMENT.

5.3 Constructive Termination.

If during the period commencing on the date that is 12 months prior to the occurrence of a Change in Control and ending on the date that is 48 months following a Change in Control, (i) the Company terminates Employee's employment, or other than for cause, the Employee terminates her employment with the Company, or (ii) the Employee terminates her employment for Good Reason (both a "constructive termination"), then;

o all stock options under any Company Stock Option Plan which Employee holds at the time of such Constructive Termination shall become fully vested;

o the Company will extend the expiration date of the stock options referred to above to a date which is four years after the effective date of the Employee's resignation, unless the expiration date is after such four-year period, in which case the original expiration date will control;

o all outstanding restricted stock, which is the subject of an Award Agreement pursuant to the Company's 2014 Incentive Stock Bonus Plan; shall vest; and

3

o all restrictions pertaining to any award made pursuant to the Company's 2014 Incentive Stock Bonus Plan shall lapse and have no further force and effect, including the failure to meet the Performance Criteria set forth in the Award Agreement pursuant to the Company's 2014 Incentive Stock Bonus Plan.

For purposes of the above:

"Change of Control" shall mean a change in ownership or control of the Company affected through any of the following transactions:

a. a merger, consolidation or reorganization approved by the Company's stockholders, unless securities representing more than 50% of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly, and in substantially the same proportion, by the persons who beneficially owned the company's outstanding voting securities immediately prior to such transaction, or

b. any stockholder-approved transfer or other disposition of all or substantially all of the Company's assets, or

c. The acquisition by any individual, entity or group of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) of 20% or more of the Company's either (1) the then outstanding shares of common stock of the Company or (2) the combined voting power of the then outstanding voting securities of the Company entitled to vote in the election of directors, or

d. a change in the composition of the Board over a period of thirty-six
(36) months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.

Good Reason means: (a) a reduction in the Employee's compensation (including benefits); or (b) the Employee being assigned any duties which are materially inconsistent with the duties of the Employee immediately prior to the occurrence of the Constructive Termination; or (c) the office at which the Employee performs her duties is more than 10 miles from the office at which the Employee performed her duties immediately prior to the occurrence of the Constructive Termination.

In the event a Constructive Termination has occurred EMPLOYEE shall, in her sole discretion, provide Company with her written notice of resignation to be effective not less than 30 days after receipt by Company, whereupon EMPLOYEE shall cease to be employed by the Company and both parties shall be relieved of further responsibility or liability to the other under this Agreement, other than as provided in this AGREEMENT. Upon receipt of such notice of resignation, Company shall promptly pay to EMPLOYEE by certified check, wire

4

transfer funds, or other form of payment reasonably acceptable to EMPLOYEE, a lump sum amount equal to 18 months salary of the EMPLOYEE at such compensation rate as is then in effect under the terms of this Agreement and any extension or renewal thereof (the "Payment"), or the value of the remaining employment contract, whichever is greater. The Payment shall not have deducted from it any charges, expenses, debts, set-offs or other deductions of any kind whatsoever except for required taxes.

5.4 In the event of a Constructive Termination, the Company shall also provide the following benefits to EMPLOYEE:

a. The EMPLOYEE's existing coverage under the Company's group health plan (and, if applicable, the existing group health coverage for eligible dependents) will end on the last day of the month in which the eligible EMPLOYEE's employment terminates. The eligible EMPLOYEE and her eligible dependents may then be eligible to elect temporary continuation coverage under the Company's group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). The eligible EMPLOYEE (and, if applicable, her eligible dependents) will be provided with a COBRA election form and notice which describe her rights to continuation coverage under COBRA. If an eligible EMPLOYEE elects COBRA continuation coverage, then the Company will pay for COBRA coverage (such payments shall not include COBRA coverage with respect to the Company's Section 125 health care reimbursement plan) for (i) eighteen (18) months, or (ii) the maximum period permitted under COBRA. If EMPLOYEE does exhaust the applicable COBRA period, the Company will reimburse EMPLOYEE for the cost of an individual health insurance policy in an amount not to exceed the amount of the monthly COBRA premium previously paid by the Company pursuant to this paragraph for the remainder of the two year period following EMPLOYEE's termination of employment. After such period of Company-paid coverage, the eligible EMPLOYEE (and, if applicable, her eligible dependents) may continue coverage at her own expense in accordance with COBRA or other applicable laws. No provision of this agreement will affect the continuation coverage rules under COBRA. Therefore, the period during which the eligible EMPLOYEE must elect to continue the Company's health plan coverage under COBRA, the length of time during which COBRA coverage will be made available to the eligible EMPLOYEE, and all the eligible EMPLOYEE's other rights and obligation under COBRA will be applied in the same manner that such rules would apply in the absence of the Plan. In the event, however, an EMPLOYEE becomes eligible for benefits under another plan prior to the expiration of the period in which the Company is paying benefit premiums, the Company shall no longer be obligated to pay such benefit premiums. The EMPLOYEE is required to notify the Company of eligibility for benefits under another plan and is expected to enroll in the new group plan at the first eligible opportunity unless EMPLOYEE chooses, at EMPLOYEE's sole expense, to continue COBRA benefits through the Company. If EMPLOYEE fails to notify the Company of EMPLOYEE's eligibility for alterative benefits, the Company shall have the right to discontinue payment of COBRA premiums upon thirty (30) days' notice to EMPLOYEE. In no event shall a cash payment be made to EMPLOYEE in lieu of the payment of COBRA premiums. The payment of COBRA premiums by the Company shall not extend the maximum eligible COBRA coverage period.

5

b. Outplacement Services. The Company will make available to EMPLOYEE, upon her request, outplacement services provided by a reputable outplacement counselor selected by the Company for a period of nine months following termination. The Company will assume the cost of all such outplacement services. In no event will a cash payment be made in lieu of outplacement benefits.

6. Confidentiality

6.1 In view of the fact that the EMPLOYEE's work for the Company will bring her into close contact with many confidential affairs of the Company not readily available to the public, the EMPLOYEE agrees:

6.1.1 To keep secret and retain in the strictest confidence, all confidential matters of the Company, including, without limitation, inventions and related proprietary information, trade secrets, patents, customer lists, methods, scientific results and related documentation in connection with any research and development undertaken by, or at the direction of, the Company, confidential pricing policies, confidential utilization review protocols and screens, confidential and proprietary operational methods and other confidential and proprietary business affairs and plans of the Company and its affiliates, learned by her heretofore or hereafter; and not to disclose them to anyone outside the Company, except in the course of performing her duties hereunder or with the Company's express written consent; and

6.1.2 To promptly deliver to the Company upon the termination of her employment with the Company, or at any time the Company may so request, all memoranda, notes, records, reports, manuals, and other documents (and all copies thereof) relating to the Company's business and all property associated therewith, which she may then possess or have under her control.

6.2 If the EMPLOYEE commits a breach, or threatens to commit a breach, of any of the provisions of Section 6.1 hereof, the Company shall have the following rights and remedies:

6.2.1 The rights and remedy to have the provisions of this Agreement specifically enforced by any court of competent jurisdiction, it being acknowledged that any such breach or threatened breach shall cause irreparable injury to the Company, and that money damages shall not provide a complete and adequate remedy to the Company;

Each of the rights and remedies enumerated above shall be independent of the other and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity.

7. Non-Competition and Non-Solicitation of Employees/Inventions, Patents and Copyrights

7.1 EMPLOYEE agrees and promises that if her employment is terminated, then, for the period of time described below, she will not be engaged in any other business or as a consultant to or general partner, employee, officer or director of any partnership, firm, corporation, or other entity, or as an agent for any person, or otherwise, if: (1) such other business, partnership, firm, corporation, entity or person is engaged in for-profit activity in the pharmaceutical industry within the United States and competes with the Company

6

in the field of natural cytokine mixtures for the treatment of any cancer indication the Company is pursuing in clinical trials; and (2) EMPLOYEE either
(a) is a senior officer of such other business, partnership, firm, corporation, entity or person; or (b) participates in or directs the development of drugs for the treatment of cancer for such other business, partnership, firm, corporation, entity or person. This agreement to refrain from engaging in competitive activities shall continue for the period during which the Company is required by the terms of paragraphs 5.2 or 5.3 of this Agreement to make salary payments to EMPLOYEE following her termination (i.e., eighteen (18) months in the case of Constructive Termination under paragraph 5.3), or for 2 years in the case of the EMPLOYEE's resignation or termination pursuant to Section 5.2.

7.2 The EMPLOYEE further agrees and represents that during the EMPLOYEE's employment by the Company and during the period in which EMPLOYEE is subject to the Non-Competition provisions of this AGREEMENT, the EMPLOYEE will not, directly or indirectly, on the EMPLOYEE's own behalf or in the service of, or on behalf of any other individual or entity, divert, or attempt to divert, solicit or hire away, to or for any individual or entity which is engaged in providing business services, any person employed by the Company, whether or not such EMPLOYEE is employed pursuant to a written agreement and whether or not such EMPLOYEE is employed for a determined period or at-will.

7.3 All inventions made by the EMPLOYEE during the employment term, which inventions apply to the Company's business, including any improvements to any invention in existence as of the date of this Agreement, will be assigned to the Company. In the event any of such inventions are of a patentable nature, EMPLOYEE agrees to apply for a patent on the invention and assign any patent rights relating to the invention to the Company. The Company will bear the costs of any such patent applications.

7.4 EMPLOYEE understands that the Company's duties may involve writing or drafting various documents, for the Company. EMPLOYEE hereby assigns any and all rights to such documents to the Company, together with the right to secure copyright therefor and all extensions and renewals of copyright throughout the entire world. The Company shall have the right to make any and all versions, omissions, additions, changes, specifications and adaptions, in whole or in part, with respect to such documents, brochures or publications.

8. Notices.

All notices, requests, consents and other communications, required or permitted to be given hereunder, shall be in writing and shall be deemed to have been duly given if delivered personally or sent by prepaid electronic transmission or mailed first-class, postage prepaid, by registered or certified mail or delivered by an overnight courier service (notices sent by electronic transmission, mail or courier service shall be deemed to have been given on the date sent, or to such other address as either party shall designate by notice in writing to the other in accordance herewith).

7

9. Arbitration

The parties agree that any and all disputes that they have with one another which arise out of EMPLOYEE's employment or under the terms of this AGREEMENT shall be resolved through final and binding arbitration, as specified herein. This shall include, without limitation, disputes relating to this AGREEMENT, EMPLOYEE's employment by the Company or the termination thereof, claims for breach of contract or breach of the covenant of good faith and fair dealing, and any claims of discrimination or other claims under any federal, state or local law or regulation now in existence or hereinafter enacted and as amended from time to time concerning in any way the subject of EMPLOYEE's employment with the Company or its termination. The only claims not covered by this paragraph 9 are claims for benefits under the workers' compensation laws or claims for unemployment insurance benefits, which will be resolved pursuant to those laws, or the Company's rights pursuant to Section 6.2.1, which may be enforced by any court of competent jurisdiction. Binding arbitration will be conducted in the Washington, D.C. metropolitan area, in accordance with the rules and regulations of the American Arbitration Association. Each party will bear one half of the cost of the arbitration filing and hearing fees, and the cost of the arbitrator. Each party will bear its own attorneys' fees, unless otherwise decided by the arbitrator. EMPLOYEE understands and agrees that the arbitration shall be instead of any civil litigation and that the arbitrator's decision shall be final and binding to the fullest extent permitted by law and enforceable by any court having jurisdiction thereof.

10. General.

10.1 This Agreement shall be governed by, and enforced in accordance with, the laws of the Commonwealth of Virginia.

10.2 The article and section headings in this Agreement are for reference only and shall not in any way affect the interpretation of this Employment Agreement.

10.3 This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof.

10.4 This Agreement, and the EMPLOYEE'S rights and obligations hereunder, may not be assigned by the EMPLOYEE. The Company may assign this Agreement and its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets subject to Section 5.3 hereof; in any event, the obligations of the Company hereunder shall be binding on its successors or assigns, whether by merger, consolidation of acquisition of all or substantially all of its business or assets.

10.5 This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms hereof may be waived, only by a written instrument executed by both of the parties hereto or, in the case of a waiver, by the party waiving compliance. The failure of either party at any time or times to require performance of any provision hereof shall in no manner affect

8

the right at a later time to enforce the same. No waiver by either party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant in this Agreement.

11. Subsidiaries and Affiliates.

As used herein, the term "subsidiary" shall mean any corporation or other business entity controlled by the corporation in question; and the term "affiliate" shall mean and include any corporation or other business entity controlling, controlled by, or under common control with the corporation in question.

12. Survival.

Sections 6 and 7 of this Agreement shall survive termination of this Agreement for any reason.

IN WITNESS WHEREOF, the parties have executed this Agreement as of August 31, 2016.

CEL-SCI CORPORATION

/s/ Geert Kersten
------------------------------------
By: Geert Kersten,
    Chief Executive Officer

EMPLOYEE

/s/ Patricia B. Prichep
------------------------------------
Patricia B. Prichep

9

EXHIBIT 10(ooo)


EMPLOYMENT AGREEMENT

This Employment Agreement ("AGREEMENT") is made by and between Eyal Talor ("EMPLOYEE") and CEL-SCI Corporation ("CEL-SCI" or "the Company") as of August 31, 2016 (the "Effective Date").

RECITALS

EMPLOYEE has been an EMPLOYEE of CEL-SCI since March 16, 1994. CEL-SCI and EMPLOYEE wish to set forth in this AGREEMENT the terms and conditions under which EMPLOYEE is to be employed by CEL-SCI from the date of execution forward.

In consideration of EMPLOYEE's agreement to continue providing services to CEL-SCI, CEL-SCI's agreement to employ EMPLOYEE on the terms and conditions set forth herein and the mutual agreements set forth herein, the parties hereto agree as follows:

1. Term And Nature Of Employment

CEL-SCI hereby employs EMPLOYEE as Chief Scientific Officer of CEL-SCI commencing on the Effective Date of this AGREEMENT and ending on August 31, 2019, unless said period of employment (the "Employment Period") is terminated earlier in accordance with the terms of this AGREEMENT. Thereafter, EMPLOYEE shall be employed on an at-will basis and may terminate and may be terminated from his employment with or without cause. EMPLOYEE hereby accepts such employment and agrees to devote his full business time and attention, best efforts, energy and skills to the business and affairs of CEL-SCI. EMPLOYEE agrees to perform such other duties as may from time to time be assigned to him by the Chief Executive Officer or the Board of Directors of CEL-SCI and shall act at all times in accordance with the best interests of CEL-SCI. EMPLOYEE agrees that he shall comply with all applicable governmental laws, rules and regulations and with all of CEL-SCI's policies, rules and/or regulations applicable to the employees of CEL-SCI.

2. Wage Compensation

2.1 EMPLOYEE shall be compensated on the basis of an annual salary of $303,453, less applicable withholding taxes. Increases in salary, if any, shall be made at the sole discretion of the Board of Directors of CEL-SCI. Nothing in this paragraph 2.1 shall be construed to limit CEL-SCI's right to terminate this AGREEMENT in accordance with the terms hereof.

2.2 Payment.

Salary payments will normally be made to EMPLOYEE semi-monthly or otherwise in accordance with CEL-SCI's pay period practices applicable to executive officers.

1

3. Other Benefits.

3.1 During the Employment Period, EMPLOYEE shall be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time Employees, in accordance with CEL-SCI's policies and practices and subject to EMPLOYEE's satisfaction of any applicable condition of eligibility.

3.2 Reimbursement of Expenses. CEL-SCI shall reimburse EMPLOYEE for all reasonable business expenses incurred by EMPLOYEE on behalf of CEL-SCI provided that: (i) such reasonable expenses are ordinary and necessary business expenses incurred on behalf of CEL-SCI, and (ii) EMPLOYEE provides CEL-SCI with itemized accounts, receipts and other documentation for such reasonable expenses as are reasonably required by CEL-SCI. Any expenses found not to be reasonable business expenses by the auditors or the IRS will be reimbursed to the Company by the EMPLOYEE.

4. Former Employment

No Conflict. EMPLOYEE represents and warrants that the execution and delivery by him of this AGREEMENT, his employment by CEL-SCI and his performance of duties under this AGREEMENT will not conflict with and will not be constrained by any prior employment or consulting agreement or relationship, or any other contractual obligations.

5. Termination

5.1.a. Termination of AGREEMENT Due to Death or Disability. EMPLOYEE's employment and this AGREEMENT shall terminate upon EMPLOYEE's death. In the event that EMPLOYEE's employment ends due to his death, CEL-SCI's obligations under this AGREEMENT shall immediately cease, except that the EMPLOYEE's legal representatives shall be entitled to receive all compensation otherwise payable to EMPLOYEE through the last day of the month in which the EMPLOYEE's death occurred. If EMPLOYEE dies while employed by CEL-SCI, any options or stock of the Company then owned by EMPLOYEE shall automatically accelerate and become fully vested. This provision shall not otherwise limit any benefits available under CEL-SCI's benefit plans. The exercise period of any stock options held by EMPLOYEE at his death will be extended pursuant to the provisions of any stock option plan or agreement pursuant to which the options were granted.

5.1.b. If EMPLOYEE becomes mentally or physically incapacitated or disabled so as to be unable to perform EMPLOYEE's duties under this agreement, the AGREEMENT shall terminate as well. Employee's inability to adequately perform services under this AGREEMENT for a period of ninety (90) consecutive days will be conclusive evidence of such mental or physical incapacity or disability, unless such inability to adequately perform such services under this AGREEMENT is pursuant to a mental or physical incapacity or disability covered by the Family Medical Leave Act ("FMLA"). If EMPLOYEE becomes disabled while employed by CEL-SCI, any options or stock of the Company then owned by EMPLOYEE shall automatically accelerate and become fully vested. This provision shall not

2

otherwise limit any benefits available under CEL-SCI's benefit plans. CEL-SCI shall also extend the period of exercisability of those stock options to four years, or the natural expiration of the stock options, whichever is later.

5.2 "Termination for Cause". Notwithstanding anything to the contrary herein, EMPLOYEE's employment and this AGREEMENT may be terminated by CEL-SCI upon written notification upon the occurrence of any of the following:

a. Willful misconduct that has a material adverse effect on CEL-SCI's operations, prospects, and business.

b. Acts of fraud against CEL-SCI.

c. EMPLOYEE breaches any of the terms or conditions set forth in this AGREEMENT and EMPLOYEE fails to cure such breach within 30 days after EMPLOYEE's receipt from CEL-SCI of written notice of such breach, which notice shall describe in reasonable detail CEL-SCI's belief that EMPLOYEE is in breach hereof (notwithstanding the following, no cure period shall be applicable to breaches by EMPLOYEE of paragraphs 6 and 7 or to the extent CEL-SCI has provided EMPLOYEE more than 2 notices of substantially the same breach within any 12 month period).

In the event that EMPLOYEE's employment is terminated with cause by CEL-SCI pursuant to this paragraph 5.2 of this AGREEMENT, CEL-SCI obligations under this AGREEMENT shall immediately cease.

Termination of EMPLOYEE pursuant to this section 5.2 shall be in addition to and without prejudice to any other right or remedy to which CEL-SCI may be entitled at law, in equity, or under this AGREEMENT.

5.3 Constructive Termination.

If during the period commencing on the date that is 12 months prior to the occurrence of a Change in Control and ending on the date that is 48 months following a Change in Control, (i) the Company terminates Employee's employment, or other than for cause, the Employee terminates his employment with the Company, or (ii) the Employee terminates his employment for Good Reason (both a "Constructive Termination"), then;

o all stock options under any Company Stock Option Plan which Employee holds at the time of such Constructive Termination shall become fully vested;

o the Company will extend the expiration date of the stock options referred to above to a date which is four years after the effective date of the Employee's resignation, unless the expiration date is after such four-year period, in which case the original expiration date will control;

o all outstanding restricted stock, which is the subject of an Award Agreement pursuant to the Company's 2014 Incentive Stock Bonus Plan; shall vest; and

3

o all restrictions pertaining to any award made pursuant to the Company's 2014 Incentive Stock Bonus Plan shall lapse and have no further force and effect, including the failure to meet the Performance Criteria set forth in the Award Agreement pursuant to the Company's 2014 Incentive Stock Bonus Plan.

For purposes of the above:

"Change of Control" shall mean a change in ownership or control of the Company affected through any of the following transactions:

a. a merger, consolidation or reorganization approved by the Company's stockholders, unless securities representing more than 50% of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly, and in substantially the same proportion, by the persons who beneficially owned the company's outstanding voting securities immediately prior to such transaction, or

b. any stockholder-approved transfer or other disposition of all or substantially all of the Company's assets, or

c. The acquisition by any individual, entity or group of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) of 20% or more of the Company's either (1) the then outstanding shares of common stock of the Company or (2) the combined voting power of the then outstanding voting securities of the Company entitled to vote in the election of directors, or

d. a change in the composition of the Board over a period of thirty-six
(36) months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.

Good Reason means: (a) a reduction in the Employee's compensation (including benefits); or (b) the Employee being assigned any duties which are materially inconsistent with the duties of the Employee immediately prior to the occurrence of the Constructive Termination; or (c) the office at which the Employee performs his duties is more than 10 miles from the office at which the Employee performed his duties immediately prior to the occurrence of the Constructive Termination.

In the event a Constructive Termination has occurred EMPLOYEE shall, in his sole discretion, provide Company with his written notice of resignation to be effective not less than 30 days after receipt by Company, whereupon EMPLOYEE shall cease to be employed by the Company and both parties shall be relieved of further responsibility or liability to the other under this Agreement, other than as provided in this AGREEMENT. Upon receipt of such notice

4

of resignation, Company shall promptly pay to EMPLOYEE by certified check, wire transfer funds, or other form of payment reasonably acceptable to EMPLOYEE, a lump sum amount equal to 18 months salary of the EMPLOYEE at such compensation rate as is then in effect under the terms of this Agreement and any extension or renewal thereof (the "Payment"), or the value of the remaining employment contract, whichever is greater. The Payment shall not have deducted from it any charges, expenses, debts, set-offs or other deductions of any kind whatsoever except for required taxes.

5.4 In the event of a Constructive Termination, the Company shall also provide the following benefits to EMPLOYEE:

a. The EMPLOYEE's existing coverage under the Company's group health plan (and, if applicable, the existing group health coverage for eligible dependents) will end on the last day of the month in which the eligible EMPLOYEE's employment terminates. The eligible EMPLOYEE and his eligible dependents may then be eligible to elect temporary continuation coverage under the Company's group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). The eligible EMPLOYEE (and, if applicable, his eligible dependents) will be provided with a COBRA election form and notice which describe his rights to continuation coverage under COBRA. If an eligible EMPLOYEE elects COBRA continuation coverage, then the Company will pay for COBRA coverage (such payments shall not include COBRA coverage with respect to the Company's Section 125 health care reimbursement plan) for (i) eighteen (18) months, or (ii) the maximum period permitted under COBRA. If EMPLOYEE does exhaust the applicable COBRA period, the Company will reimburse EMPLOYEE for the cost of an individual health insurance policy in an amount not to exceed the amount of the monthly COBRA premium previously paid by the Company pursuant to this paragraph for the remainder of the two year period following EMPLOYEE's termination of employment. After such period of Company-paid coverage, the eligible EMPLOYEE (and, if applicable, his eligible dependents) may continue coverage at his own expense in accordance with COBRA or other applicable laws. No provision of this agreement will affect the continuation coverage rules under COBRA. Therefore, the period during which the eligible EMPLOYEE must elect to continue the Company's health plan coverage under COBRA, the length of time during which COBRA coverage will be made available to the eligible EMPLOYEE, and all the eligible EMPLOYEE's other rights and obligation under COBRA will be applied in the same manner that such rules would apply in the absence of the Plan. In the event, however, an EMPLOYEE becomes eligible for benefits under another plan prior to the expiration of the period in which the Company is paying benefit premiums, the Company shall no longer be obligated to pay such benefit premiums. The EMPLOYEE is required to notify the Company of eligibility for benefits under another plan and is expected to enroll in the new group plan at the first eligible opportunity unless EMPLOYEE chooses, at EMPLOYEE's sole expense, to continue COBRA benefits through the Company. If EMPLOYEE fails to notify the Company of EMPLOYEE's eligibility for alterative benefits, the Company shall have the right to discontinue payment of COBRA premiums upon thirty (30) days' notice to EMPLOYEE. In no event shall a cash payment be made to EMPLOYEE in lieu of the payment of COBRA premiums. The payment of COBRA premiums by the Company shall not extend the maximum eligible COBRA coverage period.

5

b. Outplacement Services. The Company will make available to EMPLOYEE, upon his request, outplacement services provided by a reputable outplacement counselor selected by the Company for a period of nine months following termination. The Company will assume the cost of all such outplacement services. In no event will a cash payment be made in lieu of outplacement benefits.

6. Confidentiality

6.1 In view of the fact that the EMPLOYEE's work for the Company will bring his into close contact with many confidential affairs of the Company not readily available to the public, the EMPLOYEE agrees:

6.1.1 To keep secret and retain in the strictest confidence, all confidential matters of the Company, including, without limitation, inventions and related proprietary information, trade secrets, patents, customer lists, methods, scientific results and related documentation in connection with any research and development undertaken by, or at the direction of, the Company, confidential pricing policies, confidential utilization review protocols and screens, confidential and proprietary operational methods and other confidential and proprietary business affairs and plans of the Company and its affiliates, learned by his heretofore or hereafter; and not to disclose them to anyone outside the Company, except in the course of performing his duties hereunder or with the Company's express written consent; and

6.1.2 To promptly deliver to the Company upon the termination of his employment with the Company, or at any time the Company may so request, all memoranda, notes, records, reports, manuals, and other documents (and all copies thereof) relating to the Company's business and all property associated therewith, which he may then possess or have under his control.

6.2 If the EMPLOYEE commits a breach, or threatens to commit a breach, of any of the provisions of Section 6.1 hereof, the Company shall have the following rights and remedies:

6.2.1 The rights and remedy to have the provisions of this Agreement specifically enforced by any court of competent jurisdiction, it being acknowledged that any such breach or threatened breach shall cause irreparable injury to the Company, and that money damages shall not provide a complete and adequate remedy to the Company;

Each of the rights and remedies enumerated above shall be independent of the other and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity.

7. Non-Competition and Non-Solicitation of Employees/Inventions, Patents and Copyrights

7.1 EMPLOYEE agrees and promises that if his employment is terminated, then, for the period of time described below, he will not be engaged in any other business or as a consultant to or general partner, employee, officer or director of any partnership, firm, corporation, or other entity, or as an agent for any person, or otherwise, if: (1) such other business, partnership, firm, corporation, entity or person is engaged in for-profit activity in the

6

pharmaceutical industry within the United States and competes with the Company in the field of natural cytokine mixtures for the treatment of any cancer indication the Company is pursuing in clinical trials; and (2) EMPLOYEE either
(a) is a senior officer of such other business, partnership, firm, corporation, entity or person; or (b) participates in or directs the development of drugs for the treatment of cancer for such other business, partnership, firm, corporation, entity or person. This agreement to refrain from engaging in competitive activities shall continue for the period during which the Company is required by the terms of paragraphs 5.2 or 5.3 of this Agreement to make salary payments to EMPLOYEE following his termination (i.e., eighteen (18) months in the case of Constructive Termination under paragraph 5.3), or for 2 years in the case of the EMPLOYEE's resignation or termination pursuant to Section 5.2.

7.2 The EMPLOYEE further agrees and represents that during the EMPLOYEE's employment by the Company and during the period in which EMPLOYEE is subject to the Non-Competition provisions of this AGREEMENT, the EMPLOYEE will not, directly or indirectly, on the EMPLOYEE's own behalf or in the service of, or on behalf of any other individual or entity, divert, or attempt to divert, solicit or hire away, to or for any individual or entity which is engaged in providing business services, any person employed by the Company, whether or not such EMPLOYEE is employed pursuant to a written agreement and whether or not such EMPLOYEE is employed for a determined period or at-will.

7.3 All inventions made by the EMPLOYEE during the employment term, which inventions apply to the Company's business, including any improvements to any invention in existence as of the date of this Agreement, will be assigned to the Company. In the event any of such inventions are of a patentable nature, EMPLOYEE agrees to apply for a patent on the invention and assign any patent rights relating to the invention to the Company. The Company will bear the costs of any such patent applications.

7.4 EMPLOYEE understands that the Company's duties may involve writing or drafting various documents, for the Company. EMPLOYEE hereby assigns any and all rights to such documents to the Company, together with the right to secure copyright therefor and all extensions and renewals of copyright throughout the entire world. The Company shall have the right to make any and all versions, omissions, additions, changes, specifications and adaptions, in whole or in part, with respect to such documents, brochures or publications.

8. Notices.

All notices, requests, consents and other communications, required or permitted to be given hereunder, shall be in writing and shall be deemed to have been duly given if delivered personally or sent by prepaid electronic transmission or mailed first-class, postage prepaid, by registered or certified mail or delivered by an overnight courier service (notices sent by electronic transmission, mail or courier service shall be deemed to have been given on the date sent, or to such other address as either party shall designate by notice in writing to the other in accordance herewith).

7

9. Arbitration

The parties agree that any and all disputes that they have with one another which arise out of EMPLOYEE's employment or under the terms of this AGREEMENT shall be resolved through final and binding arbitration, as specified herein. This shall include, without limitation, disputes relating to this AGREEMENT, EMPLOYEE's employment by the Company or the termination thereof, claims for breach of contract or breach of the covenant of good faith and fair dealing, and any claims of discrimination or other claims under any federal, state or local law or regulation now in existence or hereinafter enacted and as amended from time to time concerning in any way the subject of EMPLOYEE's employment with the Company or its termination. The only claims not covered by this paragraph 9 are claims for benefits under the workers' compensation laws or claims for unemployment insurance benefits, which will be resolved pursuant to those laws, or the Company's rights pursuant to Section 6.2.1, which may be enforced by any court of competent jurisdiction. Binding arbitration will be conducted in the Washington, D.C. metropolitan area, in accordance with the rules and regulations of the American Arbitration Association. Each party will bear one half of the cost of the arbitration filing and hearing fees, and the cost of the arbitrator. Each party will bear its own attorneys' fees, unless otherwise decided by the arbitrator. EMPLOYEE understands and agrees that the arbitration shall be instead of any civil litigation and that the arbitrator's decision shall be final and binding to the fullest extent permitted by law and enforceable by any court having jurisdiction thereof.

10. General.

10.1 This Agreement shall be governed by, and enforced in accordance with, the laws of the Commonwealth of Virginia.

10.2 The article and section headings in this Agreement are for reference only and shall not in any way affect the interpretation of this Employment Agreement.

10.3 This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof.

10.4 This Agreement, and the EMPLOYEE'S rights and obligations hereunder, may not be assigned by the EMPLOYEE. The Company may assign this Agreement and its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets subject to Section 5.3 hereof; in any event, the obligations of the Company hereunder shall be binding on its successors or assigns, whether by merger, consolidation of acquisition of all or substantially all of its business or assets.

10.5 This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms hereof may be waived, only by a written instrument executed by both of the parties hereto or, in the case of a waiver, by the party waiving compliance. The failure of either party at any time or

8

times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. No waiver by either party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant in this Agreement.

11. Subsidiaries and Affiliates.

As used herein, the term "subsidiary" shall mean any corporation or other business entity controlled by the corporation in question; and the term "affiliate" shall mean and include any corporation or other business entity controlling, controlled by, or under common control with the corporation in question.

12. Survival.

Sections 6 and 7 of this Agreement shall survive termination of this Agreement for any reason.

IN WITNESS WHEREOF, the parties have executed this Agreement as of August 31, 2016.

CEL-SCI CORPORATION

/s/ Geert Kersten
------------------------------------
By: Geert Kersten,
    Chief Executive Officer

EMPLOYEE

/s/ Eyal Talor
------------------------------------
Eyal Talor